BioToxTech Co

BioToxTech Co Current Liabilities

The Current Liabilities of BioToxTech Co (086040.KQ) as of Nov 19, 2026 is 687.72 M KRW. In the previous year, Current Liabilities was 48.28 B KRW — a change of -98.58% (lower).

Current Liabilities

687.72 MKRW

YoY

-98.58%

Last updated:

Current Liabilities of BioToxTech Co is 2025 687.72 M KRW. Current Liabilities of BioToxTech Co was 2024 48.28 B KRW. It decreases by -98.58% lower compared to the previous year.

The BioToxTech Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
24.48 B KRW
Jan 1, 2019
22.70 B KRW
Jan 1, 2020
26.33 B KRW
Jan 1, 2021
46.25 B KRW
Jan 1, 2022
30.04 B KRW
Jan 1, 2023
42.52 B KRW
Jan 1, 2024
48.28 B KRW
Jan 1, 2025
687.72 M KRW
The BioToxTech Co Current Liabilities history
YEARCurrent LiabilitiesYoY
687.72 MKRW-98.58%
48.28 BKRW+13.54%
42.52 BKRW+41.53%
30.04 BKRW-35.05%
46.25 BKRW+75.63%
26.33 BKRW+15.99%
22.70 BKRW-7.27%
24.48 BKRW+6.42%
23.01 BKRW+12.16%
20.51 BKRW+6.19%
19.32 BKRW+121.37%
8.73 BKRW+66.48%
5.24 BKRW-30.11%
7.50 BKRW-14.96%
8.82 BKRW-59.55%
21.80 BKRW+55.02%
14.07 BKRW+67.56%
8.39 BKRW+42.51%
5.89 BKRW+190.00%
2.03 BKRW-36.91%
3.22 BKRW+49.30%
2.16 BKRW-19.97%
2.69 BKRW+147.16%
1.09 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Current Liabilities of BioToxTech Co is 687.72 M KRW in 2025.

Current Liabilities of BioToxTech Co changed from 48.28 B KRW to 687.72 M KRW, representing a -98.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioToxTech Co

All Key Metrics — BioToxTech Co